Adherence to human lung microvascular endothelial cells (HMVEC-L) of Plasmodium vivax isolates from Colombia
© De las salas et al.; licensee BioMed Central Ltd. 2013
Received: 29 July 2013
Accepted: 24 September 2013
Published: 30 September 2013
For years Plasmodium vivax has been considered the cause of benign malaria. Nevertheless, it has been observed that this parasite can produce a severe disease comparable to Plasmodium falciparum. It has been suggested that some physiopathogenic processes might be shared by these two species, such as cytoadherence. Recently, it has been demonstrated that P. vivax-infected erythrocytes (Pv-iEs) have the capacity to adhere to endothelial cells, in which intercellular adhesion molecule-1 (ICAM-1) seems to be involved in this process.
Adherence capacity of 21 Colombian isolates, from patients with P. vivax mono-infection to a microvascular line of human lung endothelium (HMVEC-L) was assessed in static conditions and binding was evaluated at basal levels or in tumor necrosis factor (TNF) stimulated cells. The adherence specificity for the ICAM-1 receptor was determined through inhibition with an anti-CD54 monoclonal antibody.
The majority of P. vivax isolates, 13 out of 21 (61.9%), adhered to the HMVEC-L cells, but P. vivax adherence was at least seven times lower when compared to the four P. falciparum isolates. Moreover, HMVEC-L stimulation with TNF led to an increase of 1.6-fold in P. vivax cytoadhesion, similar to P. falciparum isolates (1.8-fold) at comparable conditions. Also, blockage of ICAM-1 receptor with specific antibodies showed a significant 50% adherence reduction.
Plasmodium vivax isolates found in Colombia are also capable of adhering specifically in vitro to lung endothelial cells, via ICAM-1 cell receptor, both at basal state and after cell stimulation with TNF. Collectively, these findings reinforce the concept of cytoadherence for P. vivax, but here, to a different endothelial cell line and using geographical distinct isolates, thus contributing to understanding P. vivax biology.
It has been estimated that Plasmodium vivax causes around 80–300 million cases per year, mainly in the Asian and Latin American regions . For a long time P. vivax was considered the cause of benign malaria . Nevertheless, it has been observed that this species can cause severe disease similar to Plasmodium falciparum and complications caused by P. vivax mono-infection have been described, such as cerebral malaria with generalized seizures and epileptic status, severe anaemia, hepatic dysfunction and jaundice, acute lung lesion, acute respiratory distress syndrome (ARDS) and pulmonary oedema, shock, splenic rupture, acute renal failure and acute thrombocytopaenia with or without bleeding on different body sites [2–9]. Most recently, goes back to 2008 with the acquisition of P. vivax genomic sequence, it was found that around 80% of the genes are orthologous and mostly synthenic between the P. vivax and P. falciparum genomes [10–12]. Taken together this suggests that P. falciparum malaria pathogenic processes related to cytoadhesion may occur in P. vivax. Furthermore, studies performed by Anstey et al. suggested that pulmonary lesions found in P. vivax malaria could be caused by sequestration of parasitic forms within this organ . In this sense, Carvalho et al. reported that P. vivax has the ability to cytoadhere ex vivo to human lung endothelial cells (HLEC) and, to a lesser extent, to placenta cryosections. The adhesion found was similar in strength to that observed in P. falciparum, though ten times lower in number . Accordingly, Chotivanich et al. demonstrated that P. vivax isolates from Thailand have the ability to adhere to chondroitin sulphate A (CSA) and to hyaluronic acid (HA) in placental sections [15–18]. Moreover, in 2012, Bernabeu et al. reported the participation of vir 14 protein in the adherence to ICAM-1 receptor on the Chinese hamster ovary (CHO) cells transfected with human ICAM-1 (CHO-ICAM-1) cell line .
In Colombia, P. vivax continues to cause high impact on public health, with 83,255 (70.7%) cases in 2010, from a total of 117,650 reported malaria cases. Severe P. vivax malaria cases have been described primarily in newborn, children and pregnant women [9, 19, 20]. Due to the emergence of complications caused by P. vivax infection and its cytoadherence capacity, the purpose of this study was to determine the adherence capacity of Pv- iEs from Colombian patients, to human lung endothelial cells (HMVEC-L) mediated by ICAM-1 receptor in static conditions.
This study was approved by the Faculty of Medicine of the University of Antioquia’s ethics committee records 012 – 18 June, 2009. All participants agreed to voluntarily donate their blood samples after signing an informed consent.
Study area and subjects
Up to 8.5 ml of peripheral blood was collected from 21 P. vivax non-complicated malaria patients, diagnosed by the thick-smear method and confirmed by rapid diagnostic test (Bioline SD05FK80) and polymerase chain reaction (PCR) (to dismiss mixed infections at low levels). Seven patients, all from different places of the Department of Antioquia, were recruited at the University of Antioquia Malaria Group office in Medellin, and the remaining 14, at the Nuestra Señora del Carmen Hospital in El Bagre – Bajo Cauca- Department of Antioquia (7° 35′ 0″ N, 74° 48′ 0″ W). To compare the P. vivax isolates adhesion, four P. falciparum isolates were adapted to in vitro culture .
Isolation and concentration of Plasmodium vivax mature forms
Cultivation of Plasmodium falciparum blood forms
Plasmodium falciparum FCR3/Gambia strain (donated by National Institutes of Health- NIH, Laboratory of Malaria and Vector Research) were cultured following Trager and Jensen’s method . Mature stages concentration was carried out using 60% Percoll .
Isolation and concentration of Plasmodium falciparum mature forms harvested from infected patients
The four field P. falciparum isolates were adapted to an in vitro culture and were maintained as described for FCR3 strain. The mature concentration stages were obtained with 1% Gelatin flotation (Sigma G2625) . The percentage of mature forms, and the number of P. falciparum-infected erythrocytes by ml were estimated using the Neubauer chamber count, as previously described .
Human lung endothelial cells (HMVEC-L) culture
The HMVEC-L was maintained following the distributor’s protocol (Lonza CC-2527), in endothelial basal medium -2 (EBM-2) (CC-3156) supplemented with endothelial growth medium (EGM-2) MV BulletKit from Lonza-Clonetics (CC-3202) at 37°C and 5% CO2, until achieving a 70-90% confluence. The cells were then treated with Trypsin-EDTA (Lonza) and seeded in Lab-Tek II 8 wells chambers (Brand-Products).
Plasmodium vivax cytoadherence assay in static conditions
Cytoadherence assays in static conditions were performed according to Carvalho et al.. Briefly, HMVEC-L were seeded in Lab-Tek II chambers (Brand-Products), and 5 × 104 Percoll-enriched parasites per well were incubated in a total volume of 200 μL cytoadhesion medium (RPMI-1640, pH: 6.8) at 37°C for one hour in incubator agitation at 90 rpm (IKA KS 4000 IC Control). Non-adhered parasites and non-infected erythrocytes were removed by extensive washing in cytoadhesion medium. The adhered parasites were fixed using methanol for 2 min, and stained with Giemsa 1%. The number of parasites adhered were counted in a total of 200 HMVEC-L.
ICAM-1 (CD54) expression in HMVEC-L treated with TNF
The ICAM-1 expression in HMVEC-L was induced by TNF treatment (10 ng/mL; Sigma-Aldrich) for 18–22 hours. The ICAM-1 expression levels evaluation was determined in a FACS Canto II flow cytometer (BD Biosciences) using a Mouse Anti-Human CD54 monoclonal (FITC-Conjugated, Millipore) for 30 min, at 4°C in approximately 500,000 cells. The fluorescence intensity and percentage of positive cells for ICAM-1 was analysed in a minimum of 10,000 events acquired and analysed using the WinMDI 2.8 program. The adherence specificity to the ICAM-1 receptor was performed by previous incubation of HMVEC-L TNF stimulated cells with 10 μg/ml of anti-human CD54 monoclonal (clone 15,2 Serotec AbD MCA532) at room temperature for 30 min and then cytoadherence assay were performed as described.
The statistical significance of the performed comparisons was determined using the Mann–Whitney U test. Calculations were performed using the IBM-SPSS Statistics 21 program, and the charts with the Prism Software (6.01 version; GraphPad Software). Differences were considered significant when a p < 0.05.
Percentage of cytoadherence of Plasmodium vivax isolates
Average parasitaemia parasites/μL (SD)
P. vivax isolates
Cytoadherence of Plasmodium vivax and Plasmodium falciparum isolates in HMVEC-L basal and stimulated with TNF-α
Adherence (% of inhibition)
19.0 ± 1
27.0 ± 2
19.5 ± 2.5
39.5 ± 5.5
10.5 ± 1.5
33.5 ± 3.5
4.0 ± 1
24.5 ± 2.5
42.0 ± 4
51.0 ± 16
28.0 ± 3
52.0 ± 7
38.0 ± 9
58.5 ± 6.5
37.0 ± 11
81.5 ± 2.5
53.0 ± 6
77.5 ± 10.5
28.5 ± 6.5
67.5 ± 3.5
55.5 ± 7.5
69.5 ± 11.5
35.5 ± 10.5
47.0 ± 8
22.0 ± 4
48.5 ± 4.5
58.5 ± 13.4
113 ± 16.9
17 ± 7.1
53 ± 8.5
475 ± 38.2
1050 ± 74.9
97 ± 8.5
259 ± 24
201 ± 49.8
465 ± 61
Adherence of four P. falciparum isolates at basal state was 161.8 ± 196.2 and with TNF stimulation adhesion reach to 368.7 ± 429.1 (1.8-fold) and the adherence observed in the P. falciparum strain (FCR3) was 201 ± 61 parasite infected erythrocytes and after TNF stimulation it was 465 ± 498 (Table 2) (Figure 2C).
Cytoadherence of P. vivax isolates from Colombia was demonstrated using primary microvascular endothelial lung cells in static conditions as respiratory distress are one of the most frequently malaria vivax complication reported [26–29]. These assays revealed that the majority of P. vivax isolates, 13 out of 21 (61.9%), adhered to the lung endothelial cells and stimulation with TNF lead to a significant increase of 1.6-fold in P. vivax cytoadherence. Moreover, blockage of ICAM-1 receptor with specific antibodies showed a 50% significant reduction in parasite binding, thus demonstrating a P. vivax ability to adhere to the ICAM-1 receptor. As expected, P. vivax adherence was at least seven times lower in comparison to P. falciparum isolates. This latter finding is consistent with a previous report using Brazilian isolates .
The involvement of TNF in malaria pathogenesis has already been demonstrated in experimental cerebral malaria model . The TNF released by monocytes in response to the endothelium damage or in the presence of soluble factors derived from the parasite such as glycosyl-phosphatidylinositol (GP-I) and haemozoin, increases ICAM-1 levels expressed in endothelial cells, and therefore enhances leukocytes and platelets adhesion and parasite sequestration to the endothelium [30, 31]. Moreover, inflammatory co-morbidities, including bacterial infections, seem to play a key role in P. vivax clinical complications . Therefore, endothelial cells were treated with TNF prior to Pv-iEs adhesion as demonstrated. These results suggest that in an ICAM-1 overexpression scenario due to high expression of TNF allowed P. vivax to improve its adhesion ability. In order to explore this hypothesis, the ICAM-1 receptor was blocked using anti-CD54 showing an average reduction of 50% in the cytoadherence in TNF stimulated cells; even in some of the isolates was below basal levels. This demonstrates its role in cytoadherence and suggests the participation of other endothelial receptors, such as hyaluronic acid (HA) and chondroitin sulphate A (CSA). Plasmodium vivax adherence to ICAM-1 receptor has already been suggest by Carvalho et al., who demonstrated a significantly higher Pv-iEs adherence to CHO ICAM-1 transfected cells in comparison to mock CHO. The findings by Bernabeu et al. indicate the involvement of VIR-14 protein in ICAM-1 cytoadherence .
Collectively, this study reinforces the recent findings about P. vivax ability to cytoadhere to endothelial cells and highlights the importance of ICAM-1 endothelial receptors in this phenomenon.
The authors would like to thank the patients for their willingness during the samples collection, and the Nuestra Señora del Carmen Hospital staff in El Bagre – Department of Antioquia for lending us the malaria sample collecting equipment, and the clinical laboratory for letting us use their equipment. Ana María Vásquez Cardona, PhD Biology student, for her unconditional support in the experimental development of the investigation, and the Grupo Malaria. This work was supported by Colciencias (Grant 111549326146, RC-489-2009) and the Universidad de Antioquia, Colombia (CODI- Estrategia de Sostenibilidad 2013–2014). BD, AP, CS and SB were sponsored by Colciencias (Grant 111549326146, RC-489-2009) and the Universidad de Antioquia, Colombia (CODI- Estrategia de Sostenibilidad 2013–2014). FTMC is enrolled at the Programa Estratégico de Ciência, Tecnologia & Inovação nas Fundações Estaduais de Saúde (PECTI/AM Saúde) from Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM, Amazonas - Brazil). SCPL was supported by a FAPESP fellowship and CNPq-Universal grant.
- Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA: Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009, 9: 555-566. 10.1016/S1473-3099(09)70177-X.View ArticlePubMedGoogle Scholar
- Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008, 5: e128-10.1371/journal.pmed.0050128.PubMed CentralView ArticlePubMedGoogle Scholar
- Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, Lacerda MV, Alecrim M: Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis. 2010, 16: 1611-1614. 10.3201/eid1610.100685.PubMed CentralView ArticlePubMedGoogle Scholar
- Harish R, Gupta S: Plasmodium vivax malaria presenting with severe thrombocytopenia, cerebral complications and hydrocephalus. Indian J Pediatr. 2009, 76: 551-552. 10.1007/s12098-009-0087-0.View ArticlePubMedGoogle Scholar
- Kute V, Goswami J, Vanikar A, Shah P, Gumber M, Patel H, Kanodia K, Trivedi H: Unusual presentation of Plasmodium vivax: a neglected human malaria parasite. Parasitol Res. 2012, 110: 2573-2576. 10.1007/s00436-011-2776-7.View ArticlePubMedGoogle Scholar
- Zubairi* A, Fazal A, Raza A, Husain J, Beg A: Pulmonary complications of Plasmodium vivax malaria. Chest. 2012, 142: 194A-10.1378/chest.1386712.View ArticleGoogle Scholar
- George P, Alexander LM: A study on the clinical profile of complicated Plasmodium vivax mono–infections. Asian Pac J Trop Med. 2010, 3: 560-562. 10.1016/S1995-7645(10)60135-6.View ArticleGoogle Scholar
- Valecha N, Pinto RG, Turner GD, Kumar A, Rodrigues S, Dubhashi NG, Rodrigues E, Banaulikar SS, Singh R, Dash AP, Baird JK: Histopathology of fatal respiratory distress caused by Plasmodium vivax malaria. Am J Trop Med Hyg. 2009, 81: 758-762. 10.4269/ajtmh.2009.09-0348.View ArticlePubMedGoogle Scholar
- Arboleda M, Pérez MF, Fernández D, Usuga LY, Meza M: Perfil clínico y de laboratorio de los pacientes con malaria por Plasmodium vivax, hospitalizados en Apartadó, Colombia. Biomedica. 2012, 32: 58-67.PubMedGoogle Scholar
- Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M: Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis. 2008, 8: 449-454. 10.1016/S1473-3099(08)70153-1.View ArticlePubMedGoogle Scholar
- Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J, Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del Portillo HA, Essien K, Feldblyum TV, Gilson PR, Guo X, Kang’a S, Kooij TW, Korsinczky V, Meyer EV, Nene V, Paulsen I, Ralph V, Ren Q, Sargeant TJ, Salzberg SL, Stoeckert CJ, Sullivan SA: Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008, 455: 757-763. 10.1038/nature07327.PubMed CentralView ArticlePubMedGoogle Scholar
- Gupta P, Das A, Singh OP, Ghosh SK, Singh V: Assessing the genetic diversity of the vir genes in Indian Plasmodium vivax population. Acta Trop. 2012, 124: 133-139. 10.1016/j.actatropica.2012.07.002.View ArticlePubMedGoogle Scholar
- Carvalho BO, Lopes SCP, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, Mamoni R, Leite JA, Rodrigues MM, Soares IS, Oliveira TR, Wunderlich G, Lacerda MVG, Del Portillo HA, Araújo MOG, Russell B, Suwanarusk R, Snounou G, Rénia L, Costa FTM: On the cytoadhesion of Plasmodium vivax–infected erythrocytes. J Infect Dis. 2010, 202: 638-647. 10.1086/654815.View ArticlePubMedGoogle Scholar
- Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, Maguire GP: Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis. 2007, 195: 589-596. 10.1086/510756.PubMed CentralView ArticlePubMedGoogle Scholar
- Chotivanich K, Udomsangpetch R, Suwanarusk R, Pukrittayakamee S, Wilairatana P, Beeson JG, Day NP, White NJ: Plasmodium vivax adherence to placental glycosaminoglycans. PLoS One. 2012, 7: e34509-10.1371/journal.pone.0034509.PubMed CentralView ArticlePubMedGoogle Scholar
- Oliveira T, Fernandez-Becerra C, Jimenez MC, Del Portillo H, Soares I: Evaluation of the acquired immune responses to Plasmodium vivax VIR variant antigens in individuals living in malaria-endemic areas of Brazil. Malar J. 2006, 5: 83-10.1186/1475-2875-5-83.PubMed CentralView ArticlePubMedGoogle Scholar
- Fernandez-Becerra C, Pein O, de Oliveira TR, Yamamoto MM, Cassola AC, Rocha C, Soares IS, de Bragança Pereira CA, del Portillo HA: Variant proteins of Plasmodium vivax are not clonally expressed in natural infections. Mol Microbiol. 2005, 58: 648-658. 10.1111/j.1365-2958.2005.04850.x.View ArticlePubMedGoogle Scholar
- Bernabeu M, Lopez FJ, Ferrer M, Martin-Jaular L, Razaname A, Corradin G, Maier AG, del Portillo HA, Fernandez-Becerra C: Functional analysis of Plasmodium vivax VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor. Cell Microbiol. 2012, 14: 386-400. 10.1111/j.1462-5822.2011.01726.x.View ArticlePubMedGoogle Scholar
- Piñeros-Jiménez JG, Arboleda M, Jaramillo JC, Blair S: Reporte de cinco casos de malaria neonatal grave por Plasmodium vivax en Urabá, Colombia. Biomedica. 2008, 28: 471-479.View ArticlePubMedGoogle Scholar
- Carmona-Fonseca J, Maestre-B A: Incidencia de las malarias gestacional, congénita y placentaria en Urabá (Antioquia, Colombia), 2005–2007. Rev Colomb Obstet Ginecol. 2009, 60: 19-33.Google Scholar
- Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.View ArticlePubMedGoogle Scholar
- Pabón A, Álvarez G, Yánez J, Céspedes C, Rodríguez Y, Restrepo Á, Blair S: Evaluación de la prueba rápida inmunocromatográfica Binax NOW® ICT Pf/Pv para el diagnóstico del paludismo en un área endémica de Colombia. Biomedica. 2007, 27: 225-235.View ArticlePubMedGoogle Scholar
- Fernandez V, Treutiger CJ, Nash GB, Wahlgren M: Multiple adhesive phenotypes linked to rosetting binding of erythrocytes in Plasmodium falciparum malaria. Infect Immun. 1998, 66: 2969-2975.PubMed CentralPubMedGoogle Scholar
- Goodyer ID, Johnson J, Eisenthal R, Hayes DJ: Purification of mature-stage Plasmodium falciparum by gelatine flotation. Ann Trop Med Parasitol. 1994, 88: 209-211.PubMedGoogle Scholar
- Duraisingh MT, Roper C, Walliker D, Warhurst DC: Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol. 2000, 36: 955-961. 10.1046/j.1365-2958.2000.01914.x.View ArticlePubMedGoogle Scholar
- Lomar AV, Vidal JE, Lomar FP, Barbas CV, Matos GJ, Boulos M: Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis. 2005, 9: 425-430.View ArticlePubMedGoogle Scholar
- Kumar S, Melzer M, Dodds P, Watson J, Ord R: Plasmodium vivax malaria complicated by shock and ARDS. Scand J Infect Dis. 2007, 39: 255-256. 10.1080/00365540600904787.View ArticlePubMedGoogle Scholar
- Tanios MA, Kogelman L, McGovern B, Hassoun PM: Acute respiratory distress syndrome complicating Plasmodium vivax malaria. Crit Care Med. 2001, 29: 665-667. 10.1097/00003246-200103000-00037.View ArticlePubMedGoogle Scholar
- Martínez O: Síndrome de dificultad respiratoria aguda en malaria por Plasmodium vivax. Acta Med Colomb. 1996, 21: 146-150.Google Scholar
- Engwerda C, Belnoue E, Gruner AC, Renia L: Experimental models of cerebral malaria. Curr Top Microbiol Immunol. 2005, 297: 103-143. 10.1007/3-540-29967-X_4.PubMedGoogle Scholar
- Coban C, Ishii KJ, Horii T, Akira S: Manipulation of host innate immune responses by the malaria parasite. Trends Parasitol. 2007, 15: 271-278.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.